NVAXNovavax, Inc.

$2B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-58.7% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$40M-1010.1% margin

Net Income

-$43M-1085.3% margin

EPS (Diluted)

$-2.11

QoQ Revenue Growth

-35.0%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$51M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$221M

Total Liabilities

$372M

Stockholders' Equity

-$151M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$10M	-58.7%
Gross Profit	$4M	$10M	-58.7%
Operating Income	-$40M	-$44M	+7.6%
Net Income	-$43M	-$46M	+6.8%

Revenue Segments

Grant

$4M100%

NVAX Q1 2019 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena